Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12645995 | 0.84 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3LMNACNR1 | |
| SCHEMBL16675667 | 0.84 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3LMNACNR1 | |
| N-Desmethylvenlafaxine SCHEMBL5435875 | 0.83 | SLC6A2 (0.67) | SLC6A4SLC6A2SLC6A3LMNACNR1 | |
| N-Desmethylvenlafaxine SCHEMBL734652 | 0.83 | SLC6A2 (0.67) | SLC6A4SLC6A2SLC6A3LMNACNR1 | |
| N-Desmethylvenlafaxine SCHEMBL5439972 | 0.83 | SLC6A2 (0.67) | SLC6A4SLC6A2SLC6A3LMNACNR1 | |
| SCHEMBL16675669 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3LMNACNR1 | |
| SCHEMBL6392452 | 0.80 | SLC6A2 (0.71) | SLC6A4SLC6A2SLC6A3LMNACNR1 | |
| SCHEMBL16675666 | 0.76 | SLC6A2 (0.57) | SLC6A4SLC6A2SLC6A3LMNACNR1 | |
| SCHEMBL16675665 | 0.71 | GAA (0.46) | SLC6A4SLC6A2SLC6A3LMNACNR1 | |
| SCHEMBL16675670 | 0.71 | SLC6A2 (0.51) | SLC6A4SLC6A2SLC6A3LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399634-B2 | Compositions and methods for the treatment of depression | CELLIX BIO PRIVATE LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-9399634-B2 | Compositions and methods for the treatment of depression | CELLIX BIO PRIVATE LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-20150119453-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119453-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119453-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION | BRCA1, APC, MSH2 | SLC6A4 19/4885SLC6A2 95/4885SLC6A3 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.